Neuronetics

STIM

Market cap $192M

Overview Fund Activity

2.90 USD

+0.05

1.75%

At close Updated Sep 18, 1:59 PM EDT

1 day

1.75%

5 days

-15.7%

1 month

-18.08%

3 months

-14.2%

6 months

-41.3%

Year to date

94.63%

1 year

206.94%

5 years

-30.95%

10 years

-89.56%

About: Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.

Employees: 716

Healthcare Medical Devices

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

18% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 22

1% more capital invested

Capital invested by funds: $62.6M [Q1] → $63M (+$351K) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

10% less funds holding

Funds holding: 99 [Q1] → 89 (-10) [Q2]

16.99% less ownership

Funds ownership: 44.4% [Q1] → 27.42% (-16.99%) [Q2]

19% less call options, than puts

Call options by funds: $282K | Put options by funds: $350K

30% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 33

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$7

141% upside

Avg. target

$7

141% upside

High target

$7

141% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Canaccord Genuity

William Plovanic

$7

Buy

Maintained

6 Aug 2025

See Analyst Rankings

Financial journalist opinion

New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)

Over 5 million New York Medicaid members to gain access to Transcranial Magnetic Stimulation (TMS) services Over 5 million New York Medicaid members to gain access to Transcranial Magnetic Stimulation (TMS) services

New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD)

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to six new employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient's continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company's 2020 Inducement Incentive Plan.

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Neuronetics, Inc. (STIM) Q2 2025 Earnings Call Transcript

Neuronetics, Inc. (NASDAQ:STIM ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Keith J. Sullivan - President, CEO & Director Steven E.

Neuronetics, Inc. (STIM) Q2 2025 Earnings Call Transcript

Zacks Investment Research

Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates

Neuronetics (STIM) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.33 per share a year ago.

Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates

Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference

MALVERN, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that Keith Sullivan, President and Chief Executive Officer, will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. The Company is scheduled to present at 1:30pm Eastern Time the same day. The presentation will be available via the conference portal to registered attendees and presenting companies for 14 days following the event. About Neuronetics Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is delivering more treatment options to patients and physicians by offering exceptional in-office treatments that produce extraordinary results. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. In addition to selling the NeuroStar Advanced Therapy System and associated treatment sessions to customers, Neuronetics operates Greenbrook TMS Inc. (Greenbrook) treatment centers across the United States, offering NeuroStar Advanced Therapy for the treatment of MDD and other mental health disorders. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults, with more than 7.4 million treatments delivered, and is backed by the largest clinical data set of any TMS treatment system for depression, including the world's largest depression outcomes registry. Greenbrook treatment centers also offer SPRAVATO® (esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.1 Greenbrook has provided more than 1.8 million treatments to over 55,000 patients struggling with depression. The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com. Investor Contact: Mike Vallie or Mark KlausnerICR Healthcare443-213-0499 ir@neuronetics.com Media Contact: EvolveMKD646-517-4220 NeuroStar@evolvemkd.com

Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference

NeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents

Real-world data showing NeuroStar is effective in adolescents and young adults with depression from the world's largest TMS outcomes dataset Real-world data showing NeuroStar is effective in adolescents and young adults with depression from the world's largest TMS outcomes dataset

NeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents

Neuronetics Appoints New Chief Financial Officer

Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Officer following previously announced succession process

Neuronetics Appoints New Chief Financial Officer

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to one new non-executive employee as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient's continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company's 2020 Inducement Incentive Plan.

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook's Personalized Care Trial Program

NeuroStar, a Silver Sponsor at CTMSS, will also present two posters as part of the Company's ongoing commitment to clinical innovation and excellence NeuroStar, a Silver Sponsor at CTMSS, will also present two posters as part of the Company's ongoing commitment to clinical innovation and excellence

Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook's Personalized Care Trial Program

Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes

MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market opens on June 30, 2025.

Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes

See News Rankings

Charts implemented using Lightweight Charts™